UA109148C2 - Композиції на основі антитіла проти vegfr-3 - Google Patents

Композиції на основі антитіла проти vegfr-3

Info

Publication number
UA109148C2
UA109148C2 UAA201302462A UAA201302462A UA109148C2 UA 109148 C2 UA109148 C2 UA 109148C2 UA A201302462 A UAA201302462 A UA A201302462A UA A201302462 A UAA201302462 A UA A201302462A UA 109148 C2 UA109148 C2 UA 109148C2
Authority
UA
Ukraine
Prior art keywords
vegfr
antibody
compositions based
antibodies
disease
Prior art date
Application number
UAA201302462A
Other languages
English (en)
Russian (ru)
Inventor
Броніслав Пітовскі
Крішнадатт Персод
Наталі Зайєк
Original Assignee
Імклоун Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA109148(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Імклоун Ллк filed Critical Імклоун Ллк
Publication of UA109148C2 publication Critical patent/UA109148C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Цим винаходом пропонуються моноклональні антитіла проти VEGFR-3, фармацевтичні композиції, що містять згадані антитіла, та застосування вказаних антитіл у лікуванні захворювання.
UAA201302462A 2010-09-07 2011-09-01 Композиції на основі антитіла проти vegfr-3 UA109148C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07
PCT/US2011/050131 WO2012033696A1 (en) 2010-09-07 2011-09-01 Anti-vegfr-3 antibody compositions

Publications (1)

Publication Number Publication Date
UA109148C2 true UA109148C2 (uk) 2015-07-27

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201302462A UA109148C2 (uk) 2010-09-07 2011-09-01 Композиції на основі антитіла проти vegfr-3

Country Status (25)

Country Link
US (2) US8481034B2 (uk)
EP (1) EP2614081B1 (uk)
JP (1) JP2013538813A (uk)
KR (1) KR20130042601A (uk)
CN (1) CN103080133A (uk)
AR (1) AR082641A1 (uk)
AU (1) AU2011299443B2 (uk)
BR (1) BR112013005423A2 (uk)
CA (1) CA2809375C (uk)
CL (1) CL2013000607A1 (uk)
CO (1) CO6690754A2 (uk)
CR (1) CR20130065A (uk)
DO (1) DOP2013000039A (uk)
EA (1) EA023331B1 (uk)
EC (1) ECSP13012481A (uk)
ES (1) ES2568801T3 (uk)
GT (1) GT201300058A (uk)
MA (1) MA34487B1 (uk)
MX (1) MX2013002718A (uk)
PE (1) PE20131328A1 (uk)
SG (1) SG188265A1 (uk)
TW (1) TWI413527B (uk)
UA (1) UA109148C2 (uk)
WO (1) WO2012033696A1 (uk)
ZA (1) ZA201300804B (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2911681A1 (en) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
EP3244924B1 (en) * 2015-01-15 2021-04-07 Oncoquest Pharmaceuticals Inc. Methods of increasing delivery of anti-cancer agents to targets
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4669984B2 (ja) * 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
CA2624976A1 (en) 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies

Also Published As

Publication number Publication date
BR112013005423A2 (pt) 2016-06-07
CN103080133A (zh) 2013-05-01
PE20131328A1 (es) 2013-11-18
ZA201300804B (en) 2014-07-30
CA2809375A1 (en) 2012-03-15
AU2011299443A1 (en) 2013-02-14
ECSP13012481A (es) 2015-03-31
US20120058126A1 (en) 2012-03-08
MX2013002718A (es) 2013-05-01
GT201300058A (es) 2014-07-16
AU2011299443B2 (en) 2014-06-05
WO2012033696A1 (en) 2012-03-15
CO6690754A2 (es) 2013-06-17
US20130280278A1 (en) 2013-10-24
CR20130065A (es) 2013-03-21
KR20130042601A (ko) 2013-04-26
US8481034B2 (en) 2013-07-09
EP2614081B1 (en) 2016-03-16
AR082641A1 (es) 2012-12-19
EA023331B1 (ru) 2016-05-31
CA2809375C (en) 2016-02-09
MA34487B1 (fr) 2013-08-01
ES2568801T3 (es) 2016-05-04
EP2614081A1 (en) 2013-07-17
SG188265A1 (en) 2013-04-30
JP2013538813A (ja) 2013-10-17
TW201223543A (en) 2012-06-16
TWI413527B (zh) 2013-11-01
EA201390117A1 (ru) 2013-06-28
CL2013000607A1 (es) 2014-04-11
DOP2013000039A (es) 2013-04-15
US8784818B2 (en) 2014-07-22

Similar Documents

Publication Publication Date Title
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
MY163521A (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
SG178886A1 (en) Humanized anti-cdcp1 antibodies
NZ707086A (en) Anti-cd40 antibodies and methods of use
SG194701A1 (en) Anti-cd40 antibodies and methods of use
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX347020B (es) Anticuerpo contra el csf-1r.
MA34091B1 (fr) Anticorps anti-cd40
MY171841A (en) Antibody formulation
PH12017500864A1 (en) Anti-notch1 antibodies
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
WO2014163714A3 (en) Antibody drug conjugates
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions